UVAX-1107

· National Institute of Allergy and Infectious Diseases (NIAID)

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for UVAX-1107, covering 2025-05-23 to 2025-09-04. Get the full timeline:

Most recent: Clinical Trial Update: A Clinical Trial to Evaluate the Safety and Immunogenicity of Glycan-trimmed HIV-1 Nanoparticle Vaccine (UVAX-1107), Followed by Homologous or Wild-type HIV-1 Nanoparticle Vaccine (UVAX-1197) Boost, Each Adjuvanted With 3M-052-AF + Alum in Adult Participants Without HIV [Phase 1]

See pricing